keyword
MENU ▼
Read by QxMD icon Read
search

Memantine Bipolar

keyword
https://www.readbyqxmd.com/read/28503114/antidepressant-induced-dopamine-receptor-dysregulation-a-valid-animal-model-of-manic-depressive-illness
#1
REVIEW
Francesca Demontis, Francesca Serra, Gino Serra
BACKGROUND: Mania seems to be associated with an increased dopamine (DA) transmission. Antidepressant treatments can induce mania in humans and potentiated DA transmission in animals, by sensitizing DA D2 receptors in the mesolimbic system. We have suggested that the sensitization of D2 receptors may be responsible of antidepressant-induced mania. This review aims to report the experimental evidence that led to the hypothesis that antidepressant-induced DA receptors dysregulation can be considered an animal model of bipolar disorder...
April 2017: Current Neuropharmacology
https://www.readbyqxmd.com/read/28337866/fibromyalgia-and-bipolar-disorder-extent-of-comorbidity-and-therapeutic-implications
#2
M C Di Tommaso Morrison, F Carinci, G Lessiani, E Spinas, S K Kritas, G Ronconi, Al Caraffa, P Conti
Fibromyalgia (FM) is a syndrome that affects muscles and soft tissues. Presenting symptoms include chronic muscle pain, fatigue, sleep problems and psychological symptoms, including depression and anxiety. There exists strong evidence of a comorbidity between FM and Bipolar Disorder (BD). In this study, papers from 2006 to February 2016 that examined the comorbidity and etiological similarities of FM and BD were reviewed, as well as the therapeutic implications of these findings. The reviewed articles showed that an adequate psychiatric screening for BD is recommended in FM patients with depressive symptoms, in order to decrease administration of antidepressants for BD, due to the lack of proven efficacy, and to limit antidepressant-induced mania...
January 2017: Journal of Biological Regulators and Homeostatic Agents
https://www.readbyqxmd.com/read/28222534/a-meta-analysis-of-memantine-for%C3%A2-depression
#3
Taro Kishi, Shinji Matsunaga, Nakao Iwata
We conducted a systematic review and meta-analysis on whether memantine was beneficial for the treatment of depressive symptoms in major depressive disorder (MDD) and bipolar disorder (BD). The analysis included double-blind, randomized, placebo-controlled trials of memantine in MDD and BD. The primary outcome measures for efficacy and safety were response rate and all-cause discontinuation, respectively. Risk ratio (RR) and standardized mean difference with 95% confidence intervals (95% CI) were calculated...
2017: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/28114089/-non-conventional-pharmacological-agents-for-the-treatment-of-bipolar-disorder-%C3%AE-systematic-review-of-the-evidence
#4
REVIEW
K N Fountoulakis, D Balaris, V Nikolaou, J Νimatoudis
Bipolar disorder (BD) has a complex and variable clinical picture which is characterized by many different phacets and phases and as a result its therapeutical options are also complex and often unsatisfactory. Typically the so-called "mood stabilizers" are used in the treatment of BD and in this class lithium and specific antiepileptics are included. The present study aimed to systematically review the literature concerning the presence of randomized double blind clinical trials of 'non conventional' pharmaceutical treatment options...
October 2016: Psychiatrikē, Psychiatriki
https://www.readbyqxmd.com/read/28099183/memantine-as-an-adjuvant-treatment-for-obsessive-compulsive-symptoms-in-manic-phase-of-bipolar-disorder-a-randomized-double-blind-placebo-controlled-clinical-trial
#5
Ali Sahraian, Leila Razeghian Jahromi, Ahmad Ghanizadeh, Arash Mowla
PURPOSE/BACKGROUND: The aim of this study is to examine the effects of memantine as an adjuvant treatment for obsessive compulsive (OC) symptoms in patients with bipolar disorder (BD) type I, manic phase. METHODS/PROCEDURES: In this 16-week double-blind placebo-controlled randomized clinical trial, 58 patients in the manic phase of BD who had OC symptoms were randomly allocated to receive memantine or placebo plus their routine medications (lithium + olanzapine + clonazepam)...
April 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/27425857/antidepressant-induced-dopamine-receptor-dysregulation-a-valid-animal-model-of-manic-depressive-illness
#6
Francesca Demontis, Francesca Serra, Gino Serra
BACKGROUND: Mania seems to be associated with an increased dopamine (DA) transmission. Antidepressant treatments can induce mania in humans and potentiated DA transmission in animals, by sensitizing DA D2 receptors in the mesolimbic system. We have suggested that the sensitization of D2 receptors may be responsible of antidepressant-induced mania. This review aims to report the experimental evidence that led to the hypothesis that antidepressant-induced DA receptors dysregulation can be considered an animal model of bipolar disorder...
July 15, 2016: Current Neuropharmacology
https://www.readbyqxmd.com/read/27010579/acetylcholinesterase-inhibitors-and-memantine-in-bipolar-disorder-a-systematic-review-and-best-evidence-synthesis-of-the-efficacy-and-safety-for-multiple-disease-dimensions
#7
REVIEW
Nicola Veronese, Marco Solmi, Claudio Luchini, Ru-Band Lu, Brendon Stubbs, Leonardo Zaninotto, Christoph U Correll
BACKGROUND: Acetylcholinesterase inhibitors (AceI) and memantine might prove useful in bipolar disorder (BD) given their neuroprotective and pro-cognitive effects, as highlighted by several case reports. We aimed to systematically review the efficacy and safety of AceI and memantine across multiple outcome dimensions in BD. METHODS: Systematic PubMed and SCOPUS search until 04/17/2015 without language restrictions. Included were randomized controlled trials (RCTs), open label studies and case series of AceI or memantine in BD patients reporting quantitative data on depression, mania, psychotic symptoms, global functioning, or cognitive performance...
June 2016: Journal of Affective Disorders
https://www.readbyqxmd.com/read/26495149/anti-ampa-receptor-encephalitis-presenting-as-a-rapid-cycling-bipolar-disorder-in-a-young-woman-with-turner-syndrome
#8
Giuseppe Quaranta, Angelo Giovanni Icro Maremmani, Giulio Perugi
Background. Autoimmune encephalitis is a disorder characterised by the subacute onset of seizures, short-term memory loss, and psychiatric and behavioural symptoms. Initially, it was recognised as a paraneoplastic disorder, but recently a subgroup of patients without systemic cancer was identified. Case Description. We describe a 20-year-old woman with Turner syndrome presenting with a treatment-resistant rapid cycling bipolar disorder with cognitive impairment. She was diagnosed with anti-AMPA-receptor encephalitis...
2015: Case Reports in Psychiatry
https://www.readbyqxmd.com/read/26480221/pharmacological-agents-under-research-for-the-maintenance-treatment-in-bipolar-disorder
#9
REVIEW
S Dimitrakopoulos, G Konstantakopoulos
The treatment of bipolar disorder is a current challenge for clinicians and despite progress in psychopharmacology, options remain limited and results are often unsatisfactory. Current research focuses on finding new pharmaceutical agents for all phases of bipolar disorder, i.e. mania, bipolar depression and maintenance. Particularly, relapse prevention and longterm stabilization is a major therapeutic target. Combination treatment and polypharmacy are the most common choices concerning relapse prevention. Furthermore, during maintenance phase patients often experience residual mood symptoms, cognitive deficits and functional decline, which altogether illustrate the inadequate effectiveness of existing treatments and the need for new, targeted, effective and safe treatments for bipolar disorder...
July 2015: Psychiatrikē, Psychiatriki
https://www.readbyqxmd.com/read/26467409/pharmacological-approaches-for-treatment-resistant-bipolar-disorder
#10
REVIEW
Shi Hui Poon, Kang Sim, Ross J Baldessarini
Bipolar disorder is prevalent, with high risks of disability, substance abuse and premature mortality. Treatment responses typically are incomplete, especially for depressive components, so that many cases can be considered "treatment resistant." We reviewed reports on experimental treatments for such patients: there is a striking paucity of such research, mainly involving small incompletely controlled trials of add-on treatment, and findings remain preliminary. Encouraging results have been reported by adding aripiprazole, bupropion, clozapine, ketamine, memantine, pramipexole, pregabalin, and perhaps tri-iodothyronine in resistant manic or depressive phases...
2015: Current Neuropharmacology
https://www.readbyqxmd.com/read/26415966/ketamine-and-other-glutamate-receptor-modulators-for-depression-in-bipolar-disorder-in-adults
#11
REVIEW
Tayla L McCloud, Caroline Caddy, Janina Jochim, Jennifer M Rendell, Peter R Diamond, Claire Shuttleworth, Daniel Brett, Ben H Amit, Rupert McShane, Layla Hamadi, Keith Hawton, Andrea Cipriani
BACKGROUND: There is emerging evidence that glutamatergic system dysfunction might play an important role in the pathophysiology of bipolar depression. This review focuses on the use of glutamate receptor modulators for depression in bipolar disorder. OBJECTIVES: 1. To assess the effects of ketamine and other glutamate receptor modulators in alleviating the acute symptoms of depression in people with bipolar disorder.2. To review the acceptability of ketamine and other glutamate receptor modulators in people with bipolar disorder who are experiencing acute depression symptoms...
September 29, 2015: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/25661848/memantine-prevents-bipolar-like-behavior-induced-by-chronic-treatment-with-imipramine-in-rats
#12
Francesca Demontis, Marcella Falconi, Desirèe Canu, Gino Serra
A great deal of evidence suggests that virtually all antidepressant treatments induce a dopaminergic behavioral supersensitivity. We have suggested that this effect may play a key role not only in the antidepressant effect of these treatments, but also in their ability to induce a switch from depression to mania. In 2003-4 we found that the sensitization of dopamine receptors induced by imipramine is followed, after imipramine withdrawal, by a desensitization of these receptors associated with a depressive-like behavior assessed in the forced swimming test...
April 5, 2015: European Journal of Pharmacology
https://www.readbyqxmd.com/read/25650685/three-year-naturalistic-mirror-image-assessment-of-adding-memantine-to-the-treatment-of-30-treatment-resistant-patients-with-bipolar-disorder
#13
Giulia Serra, Athanasios Koukopoulos, Lavinia De Chiara, Alexia E Koukopoulos, Leonardo Tondo, Paolo Girardi, Ross J Baldessarini, Gino Serra
BACKGROUND: Developing safe and effective long-term treatments for bipolar disorder remains a major challenge. Given available treatments, patients with bipolar disorder remain unwell in half of long-term follow-up, mostly in depression. As memantine, an N-methyl-D-aspartate (NMDA)-glutamate receptor antagonist used to treat dementia, has been proposed for testing in bipolar disorder, we carried out a 3 + 3-year, mirror-image, chart-review study of the effects of adding memantine to stably continued, but insufficiently effective, ongoing mood-stabilizing treatments...
January 2015: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/25540723/memantine-new-prospective-in-bipolar-disorder-treatment
#14
REVIEW
Giulia Serra, Francesca Demontis, Francesca Serra, Lavinia De Chiara, Andrea Spoto, Paolo Girardi, Giulio Vidotto, Gino Serra
UNLABELLED: We review preclinical and clinical evidences strongly suggesting that memantine, an old drug currently approved for Alzheimer's dementia, is an effective treatment for acute mania and for the prevention of manic/hypomanic and depressive recurrences of manic-depressive illness. Lithium remains the first line for the treatment and prophylaxis of bipolar disorders, but currently available treatment alternatives for lithium resistant patients are of limited and/or questionable efficacy...
December 22, 2014: World Journal of Psychiatry
https://www.readbyqxmd.com/read/25174697/memantine-in-the-treatment-and-prophylaxis-of-bipolar-type-ii-mood-disorder-and-co-morbid-eating-disorder-a-case-report
#15
Lavinia De Chiara, Giulia Serra, Alexia Emilia Koukopoulos, Athanasios Koukopoulos, Gino Serra
We have recently reported that memantine has a clinically relevant antimanic and long-lasting mood-stabilizing effect in treatment- resistant bipolar disorders, both as augmenting agent and as a monotherapy. Moreover, we observed an acute antimanic and sustained mood-stabilizing effect also in "naïve" bipolar type I disorder. Here we report a case history of a young woman suffering from bipolar type II mood disorder, associated with a very severe eating disorder, showing an acute antimanic and a long-term prophylactic effect of memantine on bipolar disorder and comorbid eating disorder...
July 2014: Rivista di Psichiatria
https://www.readbyqxmd.com/read/24847998/memantine-in-the-treatment-and-prophylaxis-of-bipolar-ii-disorder-and-comorbid-fibromyalgia-a-case-report
#16
Giulia Serra, Lavinia DE Chiara, Alexia Emilia Koukopoulos, Athanasios Koukopoulos, Gino Serra, David A Kahn
We have recently reported that memantine has a clinically relevant antimanic and long-lasting mood-stabilizing effect in treatment-resistant bipolar disorders, both as augmenting agent and as monotherapy. We have also observed an acute antimanic and sustained mood-stabilizing effect in a small number of patients with bipolar I disorder who had had minimal previous pharmacotherapy. In this article, we report the case of a young woman suffering from bipolar II disorder with associated fibromyalgia, in whom memantine showed an acute antimanic and a long-term prophylactic effect on both bipolar disorder as well as the associated fibromyalgia syndrome...
May 2014: Journal of Psychiatric Practice
https://www.readbyqxmd.com/read/24717258/the-effects-of-add-on-low-dose-memantine-on-cytokine-levels-in-bipolar-ii-depression-a-12-week-double-blind-randomized-controlled-trial
#17
RANDOMIZED CONTROLLED TRIAL
Sheng-Yu Lee, Shiou-Lan Chen, Yun-Hsuan Chang, Po See Chen, San-Yuan Huang, Nian-Sheng Tzeng, Yu-Shan Wang, Liang-Jen Wang, I Hui Lee, Tzu-Yun Wang, Tzung Lieh Yeh, Yen Kuang Yang, Jau-Shyong Hong, Ru-Band Lu
Memantine, a noncompetitive N-methyl-d-aspartate receptor antagonist with a mood-stabilizing effect, and an association between bipolar disorder and proinflammatory cytokine levels have been reported. Whether adding-on memantine would reduce cytokine levels and is more effective than valproic acid (VPA) alone in bipolar II disorder was investigated. A randomized, double-blind, controlled, 12-week study was conducted. Patients undergoing regular VPA treatments were randomly assigned to a group: VPA + memantine (5 mg/d) (n = 106) or VPA + placebo (n = 108)...
June 2014: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/24490033/memantine-in-the-management-of-affective-recurrences-of-bipolar-disorders-after-the-discontinuation-of-long-term-lithium-treatment-three-case-histories
#18
Giulia Serra, Lavinia De Chiara, Giovanni Manfredi, Alexia E Koukopoulos, Gabriele Sani, Paolo Girardi, Athanasios Koukopoulos, Gino Serra
No abstract text is available yet for this article.
February 2014: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/24474993/a-10-week-memantine-treatment-in-bipolar-depression-a-case-report-focus-on-depressive-symptomatology-cognitive-parameters-and-quality-of-life
#19
Dominik Strzelecki, Agnieszka Tabaszewska, Zbigniew Barszcz, Olga Józefowicz, Paweł Kropiwnicki, Jolanta Rabe-Jabłońska
Memantine and other glutamatergic agents have been currently investigated in some off-label indications due to glutamatergic involvement in several psychoneurological disorders. We assumed that memantine similarly to ketamine may positively influence mood, moreover having a potential to improve cognition and general quality of life. We report a case of a 49-year-old male hospitalized during a manic and a subsequent moderate depressive episode. After an ineffective use of lithium, olanzapine and antidepressive treatment with mianserin, memantine was added up to 20 mg per day for 10 weeks...
December 2013: Psychiatry Investigation
https://www.readbyqxmd.com/read/24410564/targeting-of-nmda-receptors-in-the-treatment-of-major-depression
#20
REVIEW
Yong-Hui Dang, Xian-Cang Ma, Ji-Chun Zhang, Qian Ren, Jin Wu, Cheng-Ge Gao, Kenji Hashimoto
Major depressive disorder (MDD) is a common, recurrent mental illness that affects millions of people worldwide. Accumulating evidence suggests that the N-methyl-D-aspartate (NMDA) receptor, a subtype of glutamate receptors, plays an important role in the neurobiology and treatment of this disease. Currently, the non-competitive NMDA receptor antagonist ketamine is considered as one of the most attractive candidate drugs in therapy of treatment-resistant depression. A recent study demonstrated ketamine's rapid antidepressant activity in patients with treatment-resistant MDD and bipolar disorder...
2014: Current Pharmaceutical Design
keyword
keyword
61274
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"